Swedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. Voima Ventures and Nordic Science Investments led the private financing. Illumina Ventures, Almi Invest, Life Science Invest and several genomics-focused private investors also participated.
J&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clear
Latest NewsA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties or with the application of the drug under investigation is not yet clear.
Solutions-Based Thinking: BioDlink’s Model for Successful CDMO Partnerships
slider, Sponsored PublicationsIn an interview with European Biotechnology Magazine during J.P. Morgan Week in San Francisco, Dr. Jian Zhang, Acting CEO of BioDlink, explains how a partnership-first approach and deep ADC expertise help him offer biotech companies a competitive edge.
Forbion and Sanofi drive $75M investment in COPD biotech Altesa
Latest NewsForbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter.
Novartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural Products
Latest NewsCalifornia-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
PLL Therapeutics reports positive phase I/II data for gut-targeting ALS therapy
Latest NewsThe French biopharmaceutical company, PLL Therapeutics, announced positive results from a phase I/II clinical trial for its investigational therapy PLL001 to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that causes degeneration of motor neurons and loss of muscle control.
Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio
Latest NewsAxol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models.
Boehringer drops inhaled gene therapy for cystic fibrosis
Latest NewsSetback for Boehringer Ingelheim: the company has halted development of its inhaled gene therapy BI 3720931 for cystic fibrosis after a phase 1/2 trial failed to deliver efficacy data supporting further progress. While the safety profile met expectations, the programme has now been shelved.
US settlement: Has Bayer untied the Monsanto knot?
Latest NewsYears of uncertainty surrounding the numerous pending lawsuits against Bayer’s Monsanto unit could now be brought to an end through a costly but capped court settlement. Under the proposed agreement, Bayer would pay up to roughly 7 billion US dollars over around 20 years to resolve claims for damages.
Compass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depression
Latest NewsThe share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of two pivotal phase III trials in treatment-resistant depression (TRD), confirming consistent results across 839 patients and clearing the path toward what would be the first regulatory filing of a classic psychedelic for a psychiatric indication.
CubaseBio secures €5.9m to scale 3D spatial transcriptomics
Latest NewsSwedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. Voima Ventures and Nordic Science Investments led the private financing. Illumina Ventures, Almi Invest, Life Science Invest and several genomics-focused private investors also participated.